The outcome of CLL patients treated with obinutuzumab combined with chlorambucil improves independently of NOTCH1 mutation status, suggesting that the augmented cytotoxicity of obinutuzumab or the increased dose of the anti‐(CD20) IgG1 antibody used in the obinutuzumab‐chlorambucil schema overcomes NOTCH1 mutation‐associated resistance to rituximab (Estenfelder et al., 2016). This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.